Olmesartan: sprue-like enteropathy.
Olmesartan exposes patients to the risk of sometimes serious chronic intestinal disorders with diarrhoea (sprue-like enteropathy). As of late 2013, this adverse effect has not been reported with other angiotensin II receptor blockers (ARBs).